S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
"This Could be the Biggest Stock Story of 2023" (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
"This Could be the Biggest Stock Story of 2023" (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
Seven millionaires secretly enable market shock? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
"This Could be the Biggest Stock Story of 2023" (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
"This Could be the Biggest Stock Story of 2023" (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
Seven millionaires secretly enable market shock? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
"This Could be the Biggest Stock Story of 2023" (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
"This Could be the Biggest Stock Story of 2023" (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
Seven millionaires secretly enable market shock? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
"This Could be the Biggest Stock Story of 2023" (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
"This Could be the Biggest Stock Story of 2023" (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
Seven millionaires secretly enable market shock? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Top-Rated StocksTop-Rated
NASDAQ:IRON

Disc Medicine (IRON) Stock Forecast, Price & News

$46.98
+0.01 (+0.02%)
(As of 09/29/2023 ET)
Compare
Today's Range
$46.04
▼
$47.83
50-Day Range
$45.00
▼
$55.99
52-Week Range
$11.80
▼
$57.70
Volume
311,923 shs
Average Volume
239,818 shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.78
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Disc Medicine MarketRank™ Forecast

Analyst Rating
Buy
3.10 Rating Score
Upside/​Downside
14.5% Upside
$53.78 Price Target
Short Interest
Healthy
2.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Disc Medicine in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$19.44 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.47) to ($3.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.48 out of 5 stars

Medical Sector

913th out of 970 stocks

Pharmaceutical Preparations Industry

426th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

IRON stock logo

About Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc., together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

IRON Price History

IRON Stock News Headlines

September 20, 2023 | finance.yahoo.com
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
September 20, 2023 | americanbankingnews.com
Disc Medicine Opco Inc (NASDAQ:IRON) Short Interest Down 6.2% in August
September 30, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 6, 2023 | finance.yahoo.com
With 52% ownership, Disc Medicine Opco Inc (NASDAQ:IRON) boasts of strong institutional backing
August 30, 2023 | finance.yahoo.com
Disc Medicine to Participate in Upcoming Investor Conferences
August 22, 2023 | seekingalpha.com
Disc Medicine: Rare Disease Developer Derisking Itself
July 27, 2023 | finance.yahoo.com
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
July 26, 2023 | finance.yahoo.com
Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now
September 30, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
July 12, 2023 | investing.com
Disc Medicine Inc (IRON)
June 22, 2023 | finance.yahoo.com
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 13, 2023 | finance.yahoo.com
Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2023 | finance.yahoo.com
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 9, 2023 | finance.yahoo.com
Why Perfectly Rated Disc Medicine, With A 234% Move This Year, Just Put Up Another Big Gain
June 9, 2023 | seekingalpha.com
Disc Medicine: Soaring On EPP Data Release, Reality May Bite On Limited Market Opportunity
June 9, 2023 | finance.yahoo.com
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
June 7, 2023 | fool.com
Disc Medicine Opco (NASDAQ: IRON)
June 1, 2023 | finance.yahoo.com
Why Shares of Disc Medicine Opco Climbed This Week
May 31, 2023 | finance.yahoo.com
Disc Medicine to Participate in the Jefferies Healthcare Conference
May 19, 2023 | msn.com
Raymond James Initiates Coverage of Disc Medicine (IRON) with Outperform Recommendation
May 15, 2023 | finance.yahoo.com
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 | finance.yahoo.com
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
May 10, 2023 | finance.yahoo.com
Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season?
May 5, 2023 | finance.yahoo.com
Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable
May 4, 2023 | finance.yahoo.com
Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know
April 25, 2023 | seekingalpha.com
Disc Medicine: Undercovered, Underappreciated, Derisked, And Cash Rich
April 21, 2023 | finance.yahoo.com
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
See More Headlines
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

IRON Company Calendar

Last Earnings
8/11/2023
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IRON
CUSIP
N/A
CIK
1816736
Web
www.discmedicine.com
Phone
617-401-4400
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.78
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+14.5%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-46,830,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.88%
Return on Assets
-28.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
39.42
Quick Ratio
39.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.15 per share
Price / Book
4.63

Miscellaneous

Outstanding Shares
22,880,000
Free Float
21,800,000
Market Cap
$1.07 billion
Optionable
Not Optionable
Beta
-0.08
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. John D. Quisel Esq. (Age 52)
    J.D., Ph.D., CEO, Pres, Sec. & Director
    Comp: $750.12k
  • Ms. Joanne Bryce CPA (Age 56)
    Chief Financial Officer
    Comp: $539.32k
  • Mr. Jonathan Yu (Age 42)
    Chief Bus. Officer
    Comp: $539.32k
  • Dr. William Jacob Savage M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $571.95k
  • Dr. Brian MacDonald ChB (Age 63)
    MB, Ph.D., Founder & Chief Innovation Officer
  • Dr. Rahul Khara J.D. (Age 41)
    Pharm.D., Gen. Counsel, Compliance Officer & Sec.
  • Mr. Srikanth Venkatraman Ph.D.
    Sr. VP & Head of Chemistry
  • Ms. Hua Yang Ph.D.
    Sr. VP of Nonclinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IRON Stock - Frequently Asked Questions

Should I buy or sell Disc Medicine stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRON shares.
View IRON analyst ratings or view top-rated stocks.

What is Disc Medicine's stock price forecast for 2023?

10 brokerages have issued 12-month price objectives for Disc Medicine's stock. Their IRON share price forecasts range from $30.00 to $75.00. On average, they predict the company's share price to reach $53.78 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for IRON or view top-rated stocks among Wall Street analysts.

How have IRON shares performed in 2023?

Disc Medicine's stock was trading at $17.95 on January 1st, 2023. Since then, IRON stock has increased by 161.7% and is now trading at $46.98.
View the best growth stocks for 2023 here.

Are investors shorting Disc Medicine?

Disc Medicine saw a increase in short interest in September. As of September 15th, there was short interest totaling 587,400 shares, an increase of 17.0% from the August 31st total of 502,000 shares. Based on an average trading volume of 211,400 shares, the days-to-cover ratio is currently 2.8 days.
View Disc Medicine's Short Interest.

When is Disc Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IRON earnings forecast.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.12.

What ETFs hold Disc Medicine's stock?

ETFs with the largest weight of Disc Medicine (NASDAQ:IRON) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Disc Medicine's stock symbol?

Disc Medicine trades on the NASDAQ under the ticker symbol "IRON."

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Disc Medicine's stock price today?

One share of IRON stock can currently be purchased for approximately $46.98.

How much money does Disc Medicine make?

Disc Medicine (NASDAQ:IRON) has a market capitalization of $1.07 billion.

How can I contact Disc Medicine?

Disc Medicine's mailing address is 297 Boston Post Road #248, Wayland MA, 01778. The official website for the company is www.discmedicine.com. The company can be reached via phone at 617-401-4400 or via email at ir@geminitherapeutics.com.

This page (NASDAQ:IRON) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -